Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Strategy for developing and optimizing liquid chromatography methods in pharmaceutical development using

Weiyong Li1, Henrik T Rasmussen

  • 1Global Analytical Development, Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), 1000 Route 202, Raritan, NJ 08869, USA. wli@prdus.jnj.com

Journal of Chromatography. A
|November 7, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The TNF-α-FABP4-Dhhc7 Axis Mediates Olanzapine-Induced Insulin Resistance in Rats and Humans.

Clinical and experimental pharmacology & physiology·2026
Same author

Akkermansia muciniphila Alleviates Olanzapine-Induced Hepatic Steatosis via the Gut Microbiota-IGFBP2/APOA1-Liver Axis.

Microbial biotechnology·2025
Same author

Correction: Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects.

Scientific reports·2025
Same author

Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects.

Scientific reports·2025
Same author

Pharmacokinetic and Bioequivalence Evaluation of Ulipristal Acetate in Healthy Chinese Subjects in the Fasting and Postprandial Conditions.

Clinical pharmacology in drug development·2025
Same author

Gut microbiota of patients insusceptible to olanzapine-induced fatty liver disease relieves hepatic steatosis in rats.

American journal of physiology. Gastrointestinal and liver physiology·2024

This study presents a streamlined three-step strategy for developing and optimizing high-performance liquid chromatography (HPLC) methods for pharmaceutical assays and impurity analysis. The approach utilizes computer simulations and experimental designs to efficiently refine separation parameters.

Area of Science:

  • Analytical Chemistry
  • Pharmaceutical Analysis

Background:

  • Developing robust HPLC methods for pharmaceutical assays and impurity profiling is critical for drug quality control.
  • Traditional method development can be time-consuming and resource-intensive.

Purpose of the Study:

  • To introduce and validate a three-step strategy for efficient HPLC method development and optimization.
  • To reduce the number of experimental runs required for method development.

Main Methods:

  • Utilized a column-switching system for rapid screening of multiple columns and mobile phases.
  • Employed chromatography optimization software (DryLab) for computer simulations based on two gradient runs.
  • Applied Plackett-Burman experimental designs for multi-factor optimization of critical method parameters.

Related Experiment Videos

Main Results:

  • The combined simulation and experimental design approach significantly reduced method development time and runs.
  • Identified key method parameters (e.g., column temperature, detection wavelength) influencing assay precision, accuracy, sensitivity, and specificity.
  • Graphical presentation of data (main effect plots) facilitated easy interpretation for developers and end-users.

Conclusions:

  • The described three-step strategy offers an efficient and effective approach to HPLC method development and optimization in pharmaceutical analysis.
  • Computer simulations and design of experiments are powerful tools for streamlining complex analytical method development.